February 1954


Author Affiliations

From the National Jewish Hospital and the Pediatric Service, University of Colorado School of Medicine.; Clinical Instructor in Pediatrics, University of Colorado School of Medicine, Attending in Pediatrics, National Jewish Hospital (Dr. Robinson); Fellow in Pediatrics, National Jewish Hospital (Dr. Ro).

AMA Am J Dis Child. 1954;87(2):139-155. doi:10.1001/archpedi.1954.02050090127001

I. INTRODUCTION  THE PAST decade has seen a new and satisfying impetus to the study and treatment of all forms of tuberculosis, but particularly of tuberculous meningitis, a disease heretofore of interest as a diagnostic problem only.1 However, because of its uniformly fatal outcome, after the establishment of the diagnosis interest in therapeusis was at a low ebb.Since the advent of new antimicrobial agents against tuberculosis, especially streptomycin, p-aminosalicylic acid (PAS), thiazolsulfone (Promizole), and, more recently, isoniazid (isonicotinic acid hydrazide) our attitude toward tuberculous meningitis has become a much more optimistic and positive one. There is no question that the life of a patient with this disease can be prolonged, in many cases for a long period of time. Whether or not these patients are permanently cured, we still do not know. Reports of relapses three to four years after the onset of therapy continue to filter

First Page Preview View Large
First page PDF preview
First page PDF preview